Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: J Gene Med. 2017 Mar;19(3):10.1002/jgm.2942. doi: 10.1002/jgm.2942

Figure 5. OV-ChaseM plus TMZ combination therapy enhances murine survival.

Figure 5

GBM30 glioma neurospheres were implanted into the striatum of athymic mice (n=10/group). Seven days post tumor implant, mice were treated with 3×105 pfu of OV-ChaseM via intratumoral injection and 10 mg/kg of TMZ via daily oral gavage on Days 8 through 12. Survival was assessed via Kaplan-Meir survival curves. *indicates OV‐ChaseM+10 mg/kg TMZ differences when compared to all other treatment groups with p<0.02, n=10/group.